Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of tacrolimus + mycophenolate mofetil versus tacrolimus + sirolimus for GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation
2010-024297-19Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Liège
- Start
- Jan 2011
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hematopoietic malignancies and graft-versus-host disease (GVHD) comparing Tacrolimus + mycophenolate mofetil with Tacrolimus + sirolimus (2 arms). Primary endpoint: 1-year progression-free survival. Started Jan 2011; status: completed.
02
Drugs
tacrolimusmycophenolate mofetilsirolimus
03
Conditions
hematopoietic malignanciesgraft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2010-024297-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024297-19.